IRIS
DI MARTINO, MARIA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.246
AS - Asia 957
EU - Europa 772
SA - Sud America 155
AF - Africa 50
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.189
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.193
IT - Italia 407
SG - Singapore 386
CN - Cina 155
IN - India 121
BR - Brasile 117
DE - Germania 91
GB - Regno Unito 89
VN - Vietnam 69
FI - Finlandia 41
HK - Hong Kong 39
CA - Canada 31
NL - Olanda 27
BD - Bangladesh 24
JO - Giordania 23
PK - Pakistan 23
ID - Indonesia 22
SE - Svezia 22
ZA - Sudafrica 15
MX - Messico 14
ES - Italia 13
FR - Francia 13
EG - Egitto 12
IQ - Iraq 12
SA - Arabia Saudita 12
CO - Colombia 11
AR - Argentina 9
JP - Giappone 9
RU - Federazione Russa 9
TR - Turchia 9
CZ - Repubblica Ceca 8
AE - Emirati Arabi Uniti 7
IR - Iran 7
LT - Lituania 7
NG - Nigeria 7
PE - Perù 7
PT - Portogallo 7
AU - Australia 6
IE - Irlanda 6
AT - Austria 5
ET - Etiopia 5
KE - Kenya 5
KR - Corea 5
LB - Libano 5
MY - Malesia 5
PL - Polonia 5
RO - Romania 5
UA - Ucraina 5
CY - Cipro 4
EC - Ecuador 4
UZ - Uzbekistan 4
BG - Bulgaria 3
CH - Svizzera 3
GT - Guatemala 3
MA - Marocco 3
PH - Filippine 3
VE - Venezuela 3
AL - Albania 2
HN - Honduras 2
HR - Croazia 2
LK - Sri Lanka 2
PS - Palestinian Territory 2
TH - Thailandia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BO - Bolivia 1
CM - Camerun 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PY - Paraguay 1
SN - Senegal 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 3.189
Salva come PNG Salva come JPEG
Città #
San Jose 224
Singapore 193
Ashburn 155
Chandler 110
Dallas 73
Munich 63
Santa Clara 61
Bengaluru 47
Hefei 46
Chicago 43
London 42
Beijing 30
Hong Kong 29
Turku 29
Milan 28
Lawrence 24
Princeton 24
Ho Chi Minh City 23
Rome 20
Los Angeles 19
Catanzaro 18
Hanoi 16
Amman 15
New York 15
Boardman 14
Naples 13
Carbonia 12
Helsinki 12
Parma 12
San Nicola Manfredi 12
São Paulo 12
San Francisco 10
Spezzano della Sila 10
Atlanta 9
Chennai 9
Council Bluffs 9
Montreal 9
Palermo 9
Wilmington 9
Delhi 8
Frankfurt am Main 8
Irbid 8
Madrid 8
Catania 7
Cosenza 7
Des Moines 7
Kaunas 7
Ottawa 7
Tokyo 7
Afragola 6
Buffalo 6
Da Nang 6
Ercolano 6
Hyderabad 6
Jeddah 6
Riyadh 6
Santo Stefano di Rogliano 6
Sezze 6
Ahmedabad 5
Brooklyn 5
Cape Town 5
Cardiff 5
Haiphong 5
Lucknow 5
Melito di Porto Salvo 5
Meppel 5
Nairobi 5
Olomouc 5
Orem 5
Pune 5
Sacramento 5
Seattle 5
Warsaw 5
Addis Ababa 4
Biên Hòa 4
Bologna 4
Dhaka 4
Hanover 4
Islamabad 4
Istanbul 4
Johannesburg 4
Kuala Lumpur 4
Lima 4
Manchester 4
Melbourne 4
Nicosia 4
Oristano 4
Perugia 4
Redmond 4
Stockholm 4
Tanta 4
Tashkent 4
The Dalles 4
Toronto 4
Tubarão 4
West Jordan 4
Acquaviva delle Fonti 3
Ajman 3
Amsterdam 3
Ankara 3
Totale 1.815
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 454
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 138
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 110
miR-22 suppresses DNA ligase III addiction in multiple myeloma 102
Augmented reality (AR) in minimally invasive surgery (MIS) training: where are we now in Italy? The Italian Society of Endoscopic Surgery (SICE) ARMIS survey 102
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 93
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 86
A 46,XY Female with a 9p24.3p24.1 Deletion and a 8q24.11q24.3 Duplication: A Case Report and Review of the Literature. 81
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 78
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 78
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 76
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 75
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 74
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 73
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 71
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 70
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 66
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 65
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 64
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 61
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 61
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 61
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 59
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 59
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 59
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 56
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 54
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 54
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 51
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 50
An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery 50
Mmrf-commpass data integration and analysis for identifying prognostic markers 50
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 48
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 46
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 46
Ethical Perspectives on Pharmacogenomic Profiling 45
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 44
LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation 44
null 43
A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer 39
The EASY-NET research programme: background, structure, and methodology 36
Current status of liver surgery for non-colorectal non-neuroendocrine liver metastases: the NON.LI.MET. Italian Society for Endoscopic Surgery and New Technologies (SICE) and Association of Italian Surgeons in Europe (ACIE) collaborative international survey 36
Hit identification of novel small molecules interfering with MALAT1 triplex by a structure-based virtual screening 36
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 35
The potential role of miRNAs in multiple myeloma therapy 34
null 31
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 30
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 13
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 9
null 4
Totale 3.300
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.438
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.438
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110 0 0 0 0 0 0 0 0 0 9 1 0
2021/2022126 3 0 0 22 5 0 4 21 34 15 17 5
2022/2023394 55 25 28 13 45 26 6 25 49 40 55 27
2023/2024476 90 33 42 39 45 71 25 41 10 18 27 35
2024/2025876 75 20 27 37 64 119 64 55 55 21 142 197
2025/20261.332 108 154 126 149 168 80 211 74 157 105 0 0
Totale 3.300